《大行报告》瑞信料吉利(00175.HK)第四季销量同比转正数 重申「跑赢大市」评级
瑞信报告指吉利(00175.HK)8月份的批发量按年下跌19%至10.12万辆,大致符合市场预期。由於8月份首三周的销量已录27%跌幅,因此不认为市场会对此表现感到惊讶。该行认为,销量疲弱主要是受到吉利的旧产品拖累,在8月份录得35%下跌,虽然旧产品具有价格相宜的吸引力,但却被对手以进取的价格优惠推出新产品所抵销。
至於吉利的新产品在过去六个月的表现稳定在每月20,000辆的水平。展望未来,该行预期公司的销量将会在第四季转为正增长,因为会受到强劲的新产品计划推动,将在2019至2022年间每年有超过6个新型号推出。重申其「跑赢大市」投资评级,目标价维持在14元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.